Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Part of paid clinical trials in Tampa, Florida.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT07030400
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bruton's tyrosine kinase inhibitor — DRUG
    BTKi
  • B-Cell Lymphoma 2 Protein Inhibitor — DRUG
    BCL2i

Study Details

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.

Key Dates

Start date
Jul 17, 2025
Status verified
Mar 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Bruton's tyrosine kinase inhibitor treatment
    Patients treated with a Bruton's tyrosine kinase inhibitor.
  • Arm: B-Cell Lymphoma 2 Protein Inhibitor treatment
    Patients treated with a B-Cell Lymphoma 2 Protein Inhibitor.

Primary Outcome Measure

Health Related Quality of Life (HRQOL) [ Time Frame: Up to 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612
Sara Tinsley-Vance, PhD, APRN, AOCN (PRINCIPAL_INVESTIGATOR)
Dorothie Durosier Mertilus, PhD (SUB_INVESTIGATOR)
Richie Reich, PhD (SUB_INVESTIGATOR)

Find similar trials in Tampa, FL

By research site
Moffitt Cancer Center· Tampa, FL

Related Studies